Sirio Europe invests in advanced manufacturing and green technologies
Manufacturing facility upgrades have substantially increased the CDMO’s production capacity and energy efficiency.
Sirio Europe — a European nutraceutical and pharmaceutical contract development and manufacturing organisation (CDMO), part of the Sirio group — has completed a major overhaul of its Brandenburg site with advanced manufacturing and green technologies.
The improvements were implemented as part of Sirio Europe’s continuous efforts to further improve the quality and sustainability of manufacturing.
The company has installed new HVAC systems, which help to reduce the risk of product contamination.
Similarly, by installing individual drying chambers, the company can control the temperature of individual products, which is more energy-efficient and improves the softgel drying process.
In addition, adding a new vegetarian softgel manufacturing line, which transfers technology from Sirio’s Guangzhou plant, is a direct response to the growing demand for plant-based nutraceuticals.
In line with the company's commitment to increased sustainability, the site upgrades will be supported by an energy-efficient block heat and power station, which is estimated to increase power output by up to 50% through combined heat and power (CHP). The technology captures and recycles heat — otherwise lost as waste — into thermal energy to power the new manufacturing equipment.
Dominique Baum, Managing Director at Sirio Europe said that installing the heat block and power station not ony benefits the environment, it also makes good business sense: "For example, softgel production uses a lot of energy as strict parameters need to be adhered to; through CHP we can now manufacture softgels at a lower cost.”
The new plant upgrades form just a small part of wider drive at the Sirio Group to implement the most sustainable manufacturing processes of any nutraceutical CDMO globally; for example, the company exclusively sources ingredients from certified, sustainable suppliers, and are members of a number of certified sustainability groups, including the Friends of the Sea (part of the World Sustainability Organisation) and Marine Stewardship Council.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance